GDC-0973 (Cobimetinib)
Catalog No. A11441
GDC-0973 (Cobimetinib,RG7420)是一种有效且高度选择性的MEK1抑制剂,IC50为4.2 nM,对MEK1的选择性选择性是对MEK2的100倍以上,并且当针对一组超过100个丝氨酸的抑制剂进行测试时,没有显示出明显的抑制作用。
- Yunping Hu, .et al. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression, Cancer Lett, 2022, Oct 28;547:215867 PMID: 35985510
- Seidel D, .et al. A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models, Biosens Bioelectron, 2019, Jan 1;123:185-194 PMID: 30201332
Catalog Num | A11441 |
---|---|
M. Wt | 530.1 |
Formula | C21H21F3IN3O2 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 934660-93-2 |
Synonyms | XL518, XL 518, XL-518, RG7420 |
SMILES | C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O |
GDC-0973 (Cobimetinib,RG7420)是一种有效且高度选择性的MEK1抑制剂,IC50为4.2 nM,对MEK1的选择性选择性是对MEK2的100倍以上,并且当针对一组超过100个丝氨酸的抑制剂进行测试时,没有显示出明显的抑制作用。
Targets
MEK1 | ||||
4.2 nM |
In vitro (25°C) | DMSO | 88 mg/mL (165.62 mM) | |
Water | Insoluble | ||
Ethanol | Warmed: 41 mg/mL (77.17 mM) | ||
In vivo | 5% DMSO+30% PEG 300+5% Tween 80+ddH2O | 4 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18.86 mL | 94.32 mL | 188.64 mL |
0.5 mM | 3.77 mL | 18.86 mL | 37.73 mL |
1 mM | 1.89 mL | 9.43 mL | 18.86 mL |
5 mM | 0.38 mL | 1.89 mL | 3.77 mL |
*The above data is based on the productmolecular weight 530.1 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.